Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Aged
Aged, 80 and over
Alzheimer Disease
/ cerebrospinal fluid
Amyloid beta-Peptides
/ cerebrospinal fluid
Biomarkers
/ cerebrospinal fluid
Cerebrospinal Fluid Shunts
Female
Humans
Hydrocephalus, Normal Pressure
/ cerebrospinal fluid
Male
Middle Aged
Neurofilament Proteins
/ cerebrospinal fluid
Peptide Fragments
/ cerebrospinal fluid
Phosphorylation
Regression Analysis
Risk Assessment
tau Proteins
/ cerebrospinal fluid
Aβ42
P-tau
T-tau
biomarkers
idiopathic normal pressure hydrocephalus
neurofilament light
neurogranin
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
16
3
2021
medline:
18
9
2021
entrez:
15
3
2021
Statut:
ppublish
Résumé
Longitudinal changes in cerebrospinal fluid (CSF) biomarkers are seldom studied. Furthermore, data on biomarker gradient between lumbar (L-) and ventricular (V-) compartments seems to be discordant. To examine alteration of CSF biomarkers reflecting Alzheimer's disease (AD)-related amyloid-β (Aβ) aggregation, tau pathology, neurodegeneration, and early synaptic degeneration by CSF shunt surgery in idiopathic normal pressure hydrocephalus (iNPH) in relation to AD-related changes in brain biopsy. In addition, biomarker levels in L- and V-CSF were compared. L-CSF was collected prior to shunt placement and, together with V-CSF, 3-73 months after surgery. Thereafter, additional CSF sampling took place at 3, 6, and 18 months after the baseline sample from 26 iNPH patients with confirmed Aβ plaques in frontal cortical brain biopsy and 13 iNPH patients without Aβ pathology. CSF Amyloid-β42 (Aβ42), total tau (T-tau), phosphorylated tau (P-tau181), neurofilament light (NFL), and neurogranin (NRGN) were analyzed with customized ELISAs. All biomarkers but Aβ42 increased notably by 140-810% in L-CSF after CSF diversion and then stabilized. Aβ42 instead showed divergent longitudinal decrease between Aβ-positive and -negative patients in L-CSF, and thereafter increase in Aβ-negative iNPH patients in both L- and V-CSF. All five biomarkers correlated highly between V-CSF and L-CSF (Aβ42 R = 0.87, T-tau R = 0.83, P-tau R = 0.92, NFL R = 0.94, NRGN R = 0.9; all p < 0.0001) but were systematically lower in V-CSF (Aβ42 14 %, T-tau 22%, P-tau 20%, NFL 32%, NRGN 19%). With APOE genotype-grouping, only Aβ42 showed higher concentration in non-carriers of allele ɛ4. Longitudinal follow up shows that after an initial post-surgery increase, T-tau, P-tau, and NRGN are stable in iNPH patients regardless of brain biopsy Aβ pathology, while NFL normalized toward its pre-shunt levels. Aβ42 as biomarker seems to be the least affected by the surgical procedure or shunt and may be the best predictor of AD risk in iNPH patients. All biomarker concentrations were lower in V- than L-CSF yet showing strong correlations.
Sections du résumé
BACKGROUND
Longitudinal changes in cerebrospinal fluid (CSF) biomarkers are seldom studied. Furthermore, data on biomarker gradient between lumbar (L-) and ventricular (V-) compartments seems to be discordant.
OBJECTIVE
To examine alteration of CSF biomarkers reflecting Alzheimer's disease (AD)-related amyloid-β (Aβ) aggregation, tau pathology, neurodegeneration, and early synaptic degeneration by CSF shunt surgery in idiopathic normal pressure hydrocephalus (iNPH) in relation to AD-related changes in brain biopsy. In addition, biomarker levels in L- and V-CSF were compared.
METHODS
L-CSF was collected prior to shunt placement and, together with V-CSF, 3-73 months after surgery. Thereafter, additional CSF sampling took place at 3, 6, and 18 months after the baseline sample from 26 iNPH patients with confirmed Aβ plaques in frontal cortical brain biopsy and 13 iNPH patients without Aβ pathology. CSF Amyloid-β42 (Aβ42), total tau (T-tau), phosphorylated tau (P-tau181), neurofilament light (NFL), and neurogranin (NRGN) were analyzed with customized ELISAs.
RESULTS
All biomarkers but Aβ42 increased notably by 140-810% in L-CSF after CSF diversion and then stabilized. Aβ42 instead showed divergent longitudinal decrease between Aβ-positive and -negative patients in L-CSF, and thereafter increase in Aβ-negative iNPH patients in both L- and V-CSF. All five biomarkers correlated highly between V-CSF and L-CSF (Aβ42 R = 0.87, T-tau R = 0.83, P-tau R = 0.92, NFL R = 0.94, NRGN R = 0.9; all p < 0.0001) but were systematically lower in V-CSF (Aβ42 14 %, T-tau 22%, P-tau 20%, NFL 32%, NRGN 19%). With APOE genotype-grouping, only Aβ42 showed higher concentration in non-carriers of allele ɛ4.
CONCLUSION
Longitudinal follow up shows that after an initial post-surgery increase, T-tau, P-tau, and NRGN are stable in iNPH patients regardless of brain biopsy Aβ pathology, while NFL normalized toward its pre-shunt levels. Aβ42 as biomarker seems to be the least affected by the surgical procedure or shunt and may be the best predictor of AD risk in iNPH patients. All biomarker concentrations were lower in V- than L-CSF yet showing strong correlations.
Identifiants
pubmed: 33720890
pii: JAD201361
doi: 10.3233/JAD-201361
pmc: PMC8150674
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Neurofilament Proteins
0
Peptide Fragments
0
amyloid beta-protein (1-42)
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1629-1642Références
J Cereb Blood Flow Metab. 2019 Jul;39(7):1355-1368
pubmed: 29485341
Neurosurgery. 2013 Jan;72(1):1-8;discussion 8
pubmed: 23037817
Ann Neurol. 2010 Oct;68(4):446-53
pubmed: 20976765
Alzheimers Res Ther. 2018 Jan 23;10(1):8
pubmed: 29370869
Fluids Barriers CNS. 2019 Jul 25;16(1):21
pubmed: 31340831
Acta Neurol Scand. 2012 Sep;126(3):145-53
pubmed: 22571428
PLoS One. 2014 Mar 17;9(3):e91974
pubmed: 24638077
Acta Neuropathol. 2012 Dec;124(6):833-45
pubmed: 23053137
Acta Neurochir (Wien). 1991;110(3-4):106-9
pubmed: 1927600
Neurology. 2014 Oct 21;83(17):1573-5
pubmed: 25332445
Neurol Med Chir (Tokyo). 2015;55(8):647-56
pubmed: 26226980
Proteomics Clin Appl. 2016 Dec;10(12):1242-1253
pubmed: 27604409
Alzheimers Dement. 2015 Oct;11(10):1180-90
pubmed: 25533203
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Alzheimers Dis. 2018;64(s1):S271-S279
pubmed: 29758941
Ann Clin Transl Neurol. 2018 Jan 11;5(2):162-171
pubmed: 29468177
Lancet Neurol. 2016 Jun;15(7):673-684
pubmed: 27068280
JAMA Neurol. 2014 Apr;71(4):476-83
pubmed: 24566866
Croat Med J. 2014 Aug 28;55(4):388-93
pubmed: 25165052
J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1119-24
pubmed: 22955176
Arch Neurol. 2006 Sep;63(9):1277-80
pubmed: 16966505
JAMA Neurol. 2019 Sep 1;76(9):1035-1048
pubmed: 31206160
Neurology. 2013 Apr 9;80(15):1385-92
pubmed: 23486875
Nat Commun. 2020 Apr 3;11(1):1683
pubmed: 32246036
J Alzheimers Dis. 2017;58(3):821-828
pubmed: 28505972
Brain Res. 2020 Jan 15;1727:146547
pubmed: 31712085
Fluids Barriers CNS. 2016 Aug 31;13(1):15
pubmed: 27581842
Alzheimers Dement. 2019 Jun;15(6):742-753
pubmed: 30967340
Adv Drug Deliv Rev. 2004 Oct 14;56(12):1825-57
pubmed: 15381336
J Alzheimers Dis. 2019;72(1):271-277
pubmed: 31561378
J Alzheimers Dis. 2015;45(1):109-15
pubmed: 25428256
Sci Transl Med. 2013 Jul 17;5(194):194re2
pubmed: 23863834
Neurosci Lett. 2001 Jan 19;297(3):187-90
pubmed: 11137759
EMBO Mol Med. 2016 Oct 4;8(10):1184-1196
pubmed: 27534871
J Alzheimers Dis. 2014;41(4):1057-62
pubmed: 24748118
Neurochem Res. 2011 Mar;36(3):528-32
pubmed: 21191652
J Cereb Blood Flow Metab. 2020 Sep;40(9):1849-1858
pubmed: 31495299
Brain. 2015 Nov;138(Pt 11):3373-85
pubmed: 26373605
Neurology. 2016 Mar 1;86(9):829-35
pubmed: 26826204
Alzheimers Dement. 2017 Jun;13(6):701-709
pubmed: 27750032
Neurology. 2003 May 13;60(9):1457-61
pubmed: 12743231
J Alzheimers Dis. 2011;25(4):583-94
pubmed: 21460434
JAMA Neurol. 2015 Nov;72(11):1275-80
pubmed: 26366630
Lancet. 2006 Jul 29;368(9533):387-403
pubmed: 16876668
PLoS One. 2012;7(4):e33606
pubmed: 22496755
Neurology. 2017 Oct 24;89(17):1782-1788
pubmed: 28939668
Acta Neuropathol. 2018 Sep;136(3):363-376
pubmed: 29700597
Alzheimers Res Ther. 2015 Jul 01;7(1):40
pubmed: 26136856
Neuropathol Appl Neurobiol. 2012 Feb;38(1):72-86
pubmed: 21696417
Arch Neurol. 2008 Aug;65(8):1102-7
pubmed: 18695061
Neurosurgery. 2005 Sep;57(3 Suppl):S4-16; discussion ii-v
pubmed: 16160425
J Alzheimers Dis. 2019;71(4):1233-1243
pubmed: 31498122
Eur J Neurol. 2007 Feb;14(2):168-73
pubmed: 17250725